DIOVAN 320 MG
VALSARTAN : 320 MG · DIN 02289504 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is DIOVAN?
DIOVAN 320 MG contains VALSARTAN : 320 MG. It is listed in the Health Canada Drug Product Database under DIN 02289504, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Feb-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIOVAN used for?
Mild to moderate essential hypertension; reduction of cardiovascular mortality in post-myocardial infarction patients; treatment of chronic heart failure in patients intolerant to ACE inhibitors.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02289504 |
|---|---|
| Brand name | DIOVAN |
| Generic / active ingredient | VALSARTAN : 320 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 320 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA03 VALSARTAN |
| AHFS class | 24:32.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Feb-2007 |
| Original market date | 2007-02-14 00:00:00 |
How is it administered?
Hypertension: 80-320 mg once daily. Post-MI: Start 20 mg BID, titrate to 160 mg BID. Heart Failure: Start 40 mg BID, titrate to 160 mg BID. Take consistently with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to section 11 of full monograph).
How is it supplied?
40 mg, 80 mg, 160 mg, and 320 mg tablets are supplied in cartons containing 2 blister strips of 14 tablets.
Contraindications
Hypersensitivity; Pregnancy and nursing; Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60ml/min/1.73m2).
Warnings and precautions
Fetal/Neonatal morbidity and death; Angioedema; Hypotension (especially in volume-depleted patients); Renal function impairment; Hyperkalemia.
What can be used instead?
Other Canadian products sharing ATC code C09CA03 VALSARTAN. 31 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-VALSARTAN | 160 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414236 |
| AURO-VALSARTAN | 320 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414244 |
| AURO-VALSARTAN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414201 |
| AURO-VALSARTAN | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414228 |
| DIOVAN | 40 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02270528 |
| DIOVAN 160MG TABLETS | 160 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02244782 |
| DIOVAN 80MG TABLETS | 80 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02244781 |
| SANDOZ VALSARTAN | 160 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02356767 |
| SANDOZ VALSARTAN | 320 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02356775 |
| SANDOZ VALSARTAN | 40 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02356740 |
Who else supplies VALSARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VALSARTAN appears in 2425 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.